Perrigo is a consumer self-care manufacturer trying to prove that store-brand share gains and a slimmer portfolio can restore earnings after a messy first half. Interim chief executive Albert Manzone inherited the Three-S plan after Patrick Lockwood-Taylor resigned in June over personal conduct that the board said did not involve the business or the accounts. The quarter is not a collapse. It is a company taking share in shrinking categories while reported profits still lean on cost timing and a completed sale.
The operating tension sits under the Core label, the go-forward perimeter that excludes infant formula and already-sold lines. Core net sales were $907 million. That print declined 3.1% as retailers cut inventory, especially in Europe, and cough-cold and summer seasonal demand started late. Share still rose about fifty basis points on both sides of the Atlantic. Earnings beat the internal plan mainly because operating expenses fell, including a one-time $6 million benefit tied to the chief executive change and a tariff recovery near $10 million.
All-in adjusted earnings per share were $0.50. Management left the full-year Core outlook unchanged rather than raising it after a beat that leaned on cost timing. Most of the Dermacosmetics cash, about $359 million, went to pay down the revolver. The equity now trades near $13.56, a multiple that already prices a long transition. The question the next several quarters resolve is whether share gains and factory absorption turn into organic growth, or whether destocking and litigation keep results stuck in a holding pattern.